Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey.

Abstract : BACKGROUND: Allergic Rhinitis is an inflammatory disease which is characterised by burdensome nasal and/or ocular symptoms. This study aimed to assess the impact of symptoms (number of symptom-free days (SFD) and Quality of Life (QoL)) in patients with Seasonal Allergic Rhinitis (SAR) being treated with fluticasone furoate (FF), mometasone furoate (MF) or fluticasone propionate (FP). METHODS: In a cross-sectional, non-interventional, cohort analysis, primary care physicians and allergy specialists in France, Germany, and Spain were recruited via telephone interviews. Each physician prospectively recruited 4 SAR patients - 2 receiving FF, 1 receiving MF and 1 receiving FP - during June 2009. Patients answered questions on symptoms and completed questionnaires on QoL (mini-rhinoconjunctivitis Quality of Life Questionnaire, RQLQ) and burden of illness (Pittsburgh Sleep Quality Index). ClinicalTrials.gov identifier: NCT01199757. RESULTS: A total of 540 patients were recruited during June 2009. 88 patients were subsequently found to be ineligible and excluded from the analyses. In the 4 weeks prior to assessment, patients reported a mean of 14.58 (+/-8.42) SFD. Patients receiving FF had more SFD (mean 15.45 +/-8.29) than patients receiving MF (adjusted mean difference -1.22, 95% Confidence Interval (CI) [-3.16 to 0.72], p=0.434) or FP (adjusted mean difference -1.95, 95% CI [-3.87 to -0.03], p=0.092), although statistical significance was not achieved. The mean RQLQ score was 1.54 (+/-1.06). Patients receiving FF had a better quality of life in the previous week (mini-RQLQ score: mean 1.42, +/-1.04) than patients receiving MF (adjusted mean difference 0.28, 95% CI [0.03 to 0.52], p=0.052) or FP (adjusted mean difference 0.18, 95% CI [-0.05 to 0.41], p=0.244) Again, none of these results achieved statistical significance. CONCLUSIONS: At the height of the allergy season, patients with SAR suffer symptoms approximately 50% of the time, and report an impact on their QoL. No significant differences were observed between FF, FP and MF related to SFD or QoL.
Type de document :
Article dans une revue
Clinical and Translational Allergy, BioMed Central, 2013, 3 (1), pp.33. 〈10.1186/2045-7022-3-33〉
Liste complète des métadonnées

Littérature citée [29 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00875331
Contributeur : Ed. Bmc <>
Soumis le : lundi 21 octobre 2013 - 17:01:22
Dernière modification le : lundi 21 octobre 2013 - 20:04:49
Document(s) archivé(s) le : vendredi 7 avril 2017 - 14:18:09

Fichiers

2045-7022-3-33.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

Citation

Mark Small, James Piercy, Pascal Demoly, Helen Marsden. Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey.. Clinical and Translational Allergy, BioMed Central, 2013, 3 (1), pp.33. 〈10.1186/2045-7022-3-33〉. 〈inserm-00875331〉

Partager

Métriques

Consultations de la notice

328

Téléchargements de fichiers

317